Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 5, 2007

View Archived Issues

Promising preclinical potential of REP-3123 to treat Clostridium difficile infections

Studies reveal further benefits of quadrivalent papillomavirus vaccination

MF59-adjuvanted H5N1 prepandemic vaccine well tolerated in adults and elderly

Reduction of biomarkers of bone resorption seen with AZD-0530 in cancer patients

AR-709 active against pneumococci, achieves high concentrations in human lungs

Novel fusion protein insulin analogue shows extended action and reduced risk of hypoglycemia

In vitro antiproliferative activity of 17-AAG in uveal melanoma

MRI reveals vascular response to MN-029 in cancer patients

Huya Bioscience licenses antiarrhythmic compound sulcardine

Metabasis HCC therapy assigned orphan medicinal product status in E.U.

CardioVascular BioTherapeutics' wound healing compound successfully completes phase I

Critical Therapeutics advances zileuton injection to phase II

NIH SBIR grant awarded to ISIS for RNAi-based drug discovery

Peptimmune's novel peptide copolymer enters phase I for MS

Tapestry commences phase II clinical evaluation of TPI-287 for advanced pancreatic cancer

Pharmasset commences combination study of R-7128 for HCV treatment

Nanobac gains option to Calgenex technology for atherosclerosis and prostatitis

New oral quinolone antibacterial agent Geninax launched in Japan

FDA accepts BLA for Cinryze and grants priority review

Recent Shionogi patent reports novel agents for cancer pain relief

New agents for inflammatory disorders claimed in recent patents

Once-yearly Aclasta approved in E.U. for postmenopausal osteoporosis

Novel therapeutic agents for neurological disorders disclosed in recent patents

Enzyme replacement therapy Elaprase receives approval in Japan

Recent patents disclose novel antipsychotic, antidepressive and anxiolytic agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...